Hydrotrope-Modified Active Agents for Mucosal Delivery

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Mucosal membranes pose a barrier to the effective delivery of active agents due to their structure and chemical properties, limiting the passive transport of both hydrophilic and lipophilic compounds, with current methods often increasing solubility at the expense of permeability.

Innovation Solution

A pharmaceutical composition comprising hydrotropes in less than 15% by weight, combined with active agents having a partition coefficient (log P or log D) between 0 and 5, enhances penetration through mucosal membranes by modifying the lipophilicity of the active agents, allowing them to bypass lipid-rich cellular membranes and intercellular lipids without increasing solubility.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If conventional methods are used to increase solubility of active agents, then solubility is improved, but permeability through mucosal membranes deteriorates

Engineering Contradiction:
ImprovesolubilityVSAvoidpermeability
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The patent modifies the lipophilicity parameter of active agents by combining them with hydrotropes, changing the partition coefficient (log P or log D) to an optimal range between 0 and 5. This parameter change enables the active agents to achieve both adequate solubility and enhanced permeability through mucosal membranes, resolving the contradiction between solubility improvement and permeability maintenance.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite system by combining active agents with hydrotropes in specific ratios. This composite approach allows the mixture to exhibit properties that neither component has alone - the hydrotropes enhance the lipophilicity and membrane permeability of the active agents while maintaining adequate solubility, thus resolving the solubility-permeability contradiction.

Inventive Principle:
Principle #40Composite materials

2Ease of operation

If passive transport is attempted through mucosal membranes, then simplicity of delivery is improved, but transport efficiency deteriorates due to membrane barriers

Engineering Contradiction:
Improvesimplicity of deliveryVSAvoidtransport efficiency
Core Design Contradiction:
Ease of operationVSProductivity

Solution Approach 1:

The patent changes the physicochemical parameters of the active agents, specifically adjusting the partition coefficient to between 0 and 5 through combination with hydrotropes. This modification enables the agents to effectively traverse the complex mucosal membrane structure through passive transport, maintaining simplicity while dramatically improving transport efficiency.

Inventive Principle:
Principle #35Parameter changes

3Quantity of substance

If active agents interact with intercellular lipids and cell membranes, then initial partitioning into mucosal tissue is improved, but overall penetration deteriorates due to binding

Engineering Contradiction:
Improvepartitioning into tissueVSAvoidpenetration
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The patent optimizes the partition coefficient (log P or log D) of active agents to a specific range between 0 and 5 through hydrotrope combination. This balanced parameter setting allows sufficient partitioning into the lipid-rich intercellular spaces while preventing excessive binding that would trap the agents, thereby achieving both good tissue partitioning and effective penetration through the mucosal barrier.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach increases the flux of active agents through mucosal membranes, improving bioavailability by reducing binding to lipids and proteins, while maintaining or enhancing permeability without the need for high concentration gradients.

Implementation Method 1

enhances penetration through mucosal membranes by modifying the lipophilicity of the active agents, allowing them to bypass lipid-rich cellular membranes and intercellular lipids

Methodology Applied
Scientific EffectLipophilicity modification:

Implementation Method 2

increases the flux of active agents through mucosal membranes, improving bioavailability by reducing binding to lipids and proteins

Methodology Applied
Scientific EffectPermeation enhancement: Permeation

Data Source

PatentUS11458201B2Mucosal active agent delivery
Publication Date: 2022.10.04 SUDA
  • US11458201B2 patent drawing
  • US11458201B2 patent drawing
  • US11458201B2 patent drawing

AI summary

A method to increase the penetration of active agents through mucosal membranes, the method comprising the step of: a) administering to a subject in need a composition comprising: i) one or more hydrotropes in a total amount of less than 15% by weight of the composition; and ii) an active agent with a partition co-efficient (log P) or distribution coefficient (log D) of between 0 and 5.